Tyra Bioscience (TYRA) Price & Analysis

Compare

104 Followers

TYRA Stock Chart & Stats

$22.03

-$0.12(-0.75%)

At close: Jan 08 4:00 PM EST

$22.03

-$0.12(-0.75%)

Day’s Range― - ―

52-Week Range$6.42 - $22.68

Previous CloseN/A

Volume80.11K

Average Volume (3M)370.94K

Market Cap

$1.18B

Enterprise Value$565.79M

Total Cash (Recent Filing)$274.92M

Total Debt (Recent Filing)$5.92M

Price to Earnings (P/E)―

Beta1.66

Next Earnings

Mar 25, 2026

EPS Estimate

-0.52

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.50

Shares Outstanding53,372,097

10 Day Avg. Volume580,167

30 Day Avg. Volume370,944

Financial Highlights & Ratios

PEG Ratio1.35

Price to Book (P/B)2.32

Price to Sales (P/S)0.00

P/FCF Ratio-11.29

Enterprise Value/Market Cap0.48

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-4.04K

Enterprise Value/Ebitda-4.62

Forecast

1Y Price Target

$32.25

Price Target Upside46.39% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical ProgressTyra is making exciting headway in dosing patients with dabo in its PhII studies in IR NMIBC and achon.

Financial StabilityStrong cash runway through 2027 spans multiple key milestones.

Treatment AdoptionOral FGFR3i offers clear adoption advantage: urologists and patients are likely to prefer a daily pill over intravesical or device-based therapies that require repeated procedures.

Bears Say

Tyra Bioscience News

Tyra Biosciences reports Q3 EPS (50c), consensus (51c)

As of September 30, 2025, TYRA had cash, cash equivalents and marketable securities of $274.9M. TYRA’s current cash,...

25d ago

TYRA

Tyra Biosciences Reports Increased Loss Amid R&D Investments

Tyra Bioscience, Inc ( ($TYRA) ) has released its Q3 earnings. Here is a breakdown of the information...

25d ago

TYRA

Tyra Biosciences price target raised to $36 from $30 at Oppenheimer

Oppenheimer analyst Matthew Biegler raised the firm’s price target on Tyra Biosciences (TYRA) to $36 from $30 and...

3M ago

TYRA

Tyra Biosciences management to meet with Oppenheimer

Meeting to be held on September 8-9 hosted by Oppenheimer. Published first on TheFly – the ultimate source...

3M ago

TYRA

Tyra Biosciences initiated with a Strong Buy at Raymond James

Raymond James initiated coverage of Tyra Biosciences (TYRA) with a Strong Buy rating and $35 price target Tyra’s...

3M ago

TYRA

Tyra Bioscience’s Promising Developments in NMIBC and Achondroplasia Drive Buy Rating

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Tyra Bioscience and keeping the price target...

3M ago

TYRA

Tyra Bioscience Begins Phase 2 Study for Achondroplasia

An announcement from Tyra Bioscience ( ($TYRA) ) is now available. On August 21, 2025, Tyra Biosciences announced...

3M ago

TYRA

Tyra Biosciences says first child dosed in BEACH301 trial

Tyra Biosciences (TYRA) announced that the first child has been dosed in BEACH301, a Phase 2 clinical study...

3M ago

TYRA

Tyra Bioscience: Strategic Advancements and Financial Stability Justify Buy Rating

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on TYRA stock, giving a Buy rating...

4M ago

TYRA

Tyra Bioscience: Promising Clinical Trials and Financial Stability Justify Buy Rating

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Tyra Bioscience and keeping the price target...

4M ago

TYRA

Tyra Biosciences Advances Clinical Programs with Strong Financial Backing

Tyra Bioscience, Inc ( ($TYRA) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

TYRA

Tyra Biosciences reports Q2 EPS (47c), consensus (51c)

As of June 30, Tyra had cash, cash equivalents, and marketable securities of $296.3M. Tyra’s current cash, cash...

4M ago

TYRA

Tyra Biosciences announces presentation on TYRA-300 preclinical results at ENDO

Tyra Biosciences (TYRA) announced that a late-breaking abstract has been accepted for presentation at The Endocrine Society’s Annual...

5M ago

TYRA

Promising Outlook for Tyra Bioscience: Buy Rating Driven by TYRA-300’s Potential in NMIBC Treatment

Tyra Bioscience (TYRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

5M ago

TYRA

TYRA FAQ

What was Tyra Bioscience’s price range in the past 12 months?

Tyra Bioscience lowest stock price was $6.42 and its highest was $22.68 in the past 12 months.

What is Tyra Bioscience’s market cap?

Tyra Bioscience’s market cap is $1.18B.

When is Tyra Bioscience’s upcoming earnings report date?

Tyra Bioscience’s upcoming earnings report date is Mar 25, 2026 which is in 114 days.

How were Tyra Bioscience’s earnings last quarter?

Tyra Bioscience released its earnings results on Nov 05, 2025. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.498 by -$0.002.

Is Tyra Bioscience overvalued?

According to Wall Street analysts Tyra Bioscience’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tyra Bioscience pay dividends?

Tyra Bioscience does not currently pay dividends.

What is Tyra Bioscience’s EPS estimate?

Tyra Bioscience’s EPS estimate is -0.52.

How many shares outstanding does Tyra Bioscience have?

Tyra Bioscience has 53,372,097 shares outstanding.

What happened to Tyra Bioscience’s price movement after its last earnings report?

Tyra Bioscience reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.498. Following the earnings report the stock price went down -3.644%.

Which hedge fund is a major shareholder of Tyra Bioscience?

Currently, no hedge funds are holding shares in TYRA

Tyra Bioscience Stock Smart Score

Neutral

Fundamentals

Return on Equity

-34.75%

Trailing 12-Months

Asset Growth

-20.69%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tyra Bioscience

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Tyra Bioscience (TYRA) Earnings & Revenues

Historic Earnings Reports

TYRA Stock 12 Month Forecast

Average Price Target

$32.25

▲(46.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","22":"$22","37":"$37","14.5":"$14.5","29.5":"$29.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,14.5,22,29.5,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.84,17.39076923076923,18.94153846153846,20.49230769230769,22.043076923076924,23.59384615384615,25.144615384615385,26.695384615384615,28.246153846153845,29.796923076923076,31.347692307692306,32.89846153846153,34.449230769230766,{"y":36,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.84,17.102307692307694,18.364615384615384,19.626923076923077,20.88923076923077,22.15153846153846,23.413846153846155,24.676153846153845,25.93846153846154,27.200769230769232,28.463076923076922,29.725384615384616,30.987692307692306,{"y":32.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.84,16.775384615384617,17.71076923076923,18.646153846153847,19.58153846153846,20.516923076923078,21.45230769230769,22.38769230769231,23.323076923076922,24.25846153846154,25.193846153846152,26.12923076923077,27.064615384615387,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.84,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.86,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.9,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.48,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.72,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.37,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.53,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >